翌圣生物 Yeasen｜生命科学试剂与诊断原料一站式平台

Abstract

Background The identification of cuproptosis offers novel insights into therapeutic strategies for neoplastic diseases. We explore whether cuproptosis and cuproptosis-related genes (CRGs) could provide novel perspectives for the prognosis and treatment of gastric cancer patients. Methods RNA sequencing data of gastric cancer patients were retrieved from The Cancer Genome Atlas Program (TCGA), CRGs in gastric cancer were analyzed through bioinformatics methods. Subsequent experiments, including Western blotting (WB), quantitative real-time polymerase chain reaction (qRT-PCR), immunofluorescence, 5-Ethynyl-2’-deoxyuridine assay, Cell Counting Kit-8 assay, Transwell assay, transmission electron microscopy, and xenograft tumor formation in nude mice, were conducted to further validate the biological role of the key CRG PDE3B in gastric cancer. Results We confirmed CP, MAP2K2, and PDE3B as key genes for the prognostic classifier. Knockdown of PDE3B effectively suppressed the pro-tumorigenic functions in gastric cancer cell malignant proliferation and progression. Elesclomol-CuCl 2 (ES-Cu) triggered canonical cuproptosis features in gastric cancer cells, and PDE3B expression was downregulated during this process. Notably, the inhibition of PDE3B significantly potentiated ES-Cu induced cuproptosis. Conclusions We characterized the landscape of CRG dysregulation in gastric cancer, verified that ES-Cu exhibited a significant cytotoxic effect on gastric cancer, and elucidated the pivotal role of PDE3B in gastric cancer.